10 questions answered from cited research · Plain language
Linvoseltamab may improve outcomes for relapsed/refractory multiple myeloma, with a 2025 indirect comparison showing longer survival and higher response rates than teclistamab, a similar bispecific antibody.
Read the full answer →Yes, real-world data shows teclistamab causes infections in about 45% of patients, with severe infections in about 23%, which is lower than clinical trial rates.
Read the full answer →The talquetamab and teclistamab combination shows a 79% overall response rate in relapsed/refractory multiple myeloma with extramedullary disease, based on the phase 2 RedirecTT-1 study.
Read the full answer →In relapsed/refractory multiple myeloma patients taking teclistamab, about 57% experience any infection and about 28% have a severe (grade ≥3) infection, based on a meta-analysis.
Read the full answer →Yes, hematologists recommend using tocilizumab to manage cytokine release syndrome (CRS) caused by bispecific antibodies in relapsed/refractory multiple myeloma, including prophylactic use in outpatient settings.
Read the full answer →The case report used a combination of ixazomib, lisaftoclax, and dexamethasone (ILD) as maintenance therapy after CAR-T cell therapy for ultra-high-risk relapsed multiple myeloma.
Read the full answer →Yes, Pomalyst is FDA-approved for both multiple myeloma and Kaposi sarcoma, including AIDS-related and HIV-negative cases.
Read the full answer →Yes, Revlimid (lenalidomide) is FDA-approved as maintenance therapy after autologous stem cell transplant for multiple myeloma.
Read the full answer →Yes, natural products like lactacystin, salinosporamide A, and polyphenols can target the proteasome, but none are approved treatments for multiple myeloma; marizomib, a natural product-derived drug, is in clinical trials.
Read the full answer →Yes, Xpovio (selinexor) in combination with dexamethasone alone is FDA-approved for heavily pretreated relapsed/refractory multiple myeloma after at least four prior therapies.
Read the full answer →